PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.91

Change

+0.02 (+0.69)%

Market Cap

N/A

Volume

0.77M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.89 (+1.40%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+6.22 (+0.91%)

USD 78.92B
ARGX argenx NV ADR

+6.87 (+1.07%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

+18.72 (+7.60%)

USD 30.22B
MRNA Moderna Inc

+1.83 (+5.37%)

USD 18.29B
RPRX Royalty Pharma Plc

-0.45 (-1.46%)

USD 18.12B
UTHR United Therapeutics Corporatio..

+9.04 (+2.52%)

USD 15.91B
SMMT Summit Therapeutics PLC

+3.07 (+16.13%)

USD 13.43B
INCY Incyte Corporation

+1.54 (+2.14%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+1.00 (+1.63%)

USD 12.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.34% 59% D- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.34% 59% D- 37% F
Trailing 12 Months  
Capital Gain -55.98% 30% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.98% 30% F 13% F
Trailing 5 Years  
Capital Gain -85.62% 41% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.62% 41% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -24.22% 17% F 9% A-
Dividend Return -24.22% 17% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.17% 92% A 68% D+
Risk Adjusted Return -92.56% 8% B- 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector